Valtrex Safety in First Trimester
Valtrex (valacyclovir) is safe to use during the first trimester of pregnancy, with decades of clinical data showing no increased risk of major birth defects compared to the general population.
Safety Profile
The FDA drug label explicitly states that clinical data over several decades with valacyclovir and its metabolite acyclovir in pregnant women have not identified a drug-associated risk of major birth defects 1. The pregnancy registry data are reassuring:
- First-trimester acyclovir exposure (756 infants): 3.2% major birth defects (95% CI: 2.0-5.0%)
- First-trimester valacyclovir exposure (28 infants): 4.5% major birth defects (95% CI: 0.24-24.9%)
- Background risk in general population: 2-4% major birth defects
These rates fall within or near the expected background risk 1.
A large Danish population-based cohort study of 837,795 live births found no association between first-trimester exposure to acyclovir or valacyclovir and major birth defects. Among 1,561 infants exposed to acyclovir, 2.0% had major birth defects (adjusted POR 0.82; 95% CI: 0.57-1.17), and among 229 infants exposed to valacyclovir, 3.1% had major birth defects (adjusted POR 1.21; 95% CI: 0.56-2.62) 2.
Important Caveat: Gastroschisis Signal
One case-control study from the National Birth Defects Prevention Study showed a 4.7-fold increased odds (95% CI: 1.7-13.3) for gastroschisis among women who used antiherpes medications between the month prior to conception and the third month of pregnancy 3. However, this study had significant limitations including demographic differences between cases and controls and possible recall bias. Notably, increased gastroschisis risk was also observed in women with genital herpes who were NOT using antiviral therapy, suggesting the association may be related to the infection itself rather than the medication 3.
Clinical Indications and Dosing
For Herpes Simplex Virus (HSV)
The 2021 CDC guidelines recommend suppressive therapy for pregnant women with a history of genital herpes starting at 36 weeks' gestation to reduce viral shedding, recurrences, and cesarean deliveries 3. Standard dosing:
- Acyclovir 400 mg three times daily, or
- Valacyclovir 500 mg twice daily
For first-trimester use, treatment would typically be for acute outbreaks rather than suppression, though the evidence supports safety if clinically indicated 4.
For Cytomegalovirus (CMV)
Recent high-quality evidence demonstrates that high-dose valacyclovir (8 g/day, given as 4 g twice daily) significantly reduces vertical transmission of CMV when maternal primary infection occurs periconceptionally or during the first trimester 5, 6, 7, 8.
A 2020 randomized controlled trial showed that among first-trimester CMV infections, only 11% of valacyclovir-treated patients had positive amniocentesis compared to 48% in the placebo group (p=0.020) 7. A 2024 individual patient data meta-analysis confirmed these findings with an adjusted odds ratio of 0.35 (95% CI: 0.16-0.76) for first-trimester infections 6.
Risk-Benefit Considerations
The risks of untreated HSV or CMV infection during pregnancy substantially outweigh any theoretical medication risks:
- Untreated first-trimester HSV: Associated with neonatal chorioretinitis, microcephaly, and skin lesions; neonatal HSV infection risk is ~1% with early pregnancy acquisition but 30-50% with third-trimester acquisition 1
- Untreated first-trimester CMV: Risk of congenital infection with microcephaly, hepatosplenomegaly, intrauterine growth restriction, and stillbirth 1
Practical Recommendations
- For HSV in first trimester: Use standard treatment doses for acute outbreaks without hesitation
- For CMV primary infection in first trimester: Consider high-dose valacyclovir (8 g/day) initiated as early as possible, continuing until amniocentesis at 21-22 weeks 7, 8
- Monitor renal function: One case of reversible acute renal failure occurred with high-dose CMV treatment 8
- Counsel patients: Reassure about the extensive safety data while acknowledging the gastroschisis signal remains incompletely understood
The evidence strongly supports that the benefits of treating active viral infections during the first trimester outweigh the minimal to absent teratogenic risk.